ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer

By WebmasterMay 24, 2022November 1st, 2024No Comments

ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer

ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint

Previous PostRenovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of Cardiology: Basic to Translational Research
Next PostImmunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38